1Robinson MK, Hodge KM, Horak E, et al. Targeting ErbB2 and ErbB3 with a bispeeific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro [ J ] - Br J Cancer, 2008, 99(9): 1415 -1425.
2Isakoff SJ, Baselga J. Trastnzumab-DM 1 : building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2- positive breast cancer [ J ]. J Clin Oncol, 2011 , 29(4) :351 -354.
3Barok M, Tanner M, Koninki K, et al. Trastuzumab-DM1 causes tumor growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer ceils in vivo [ J ]. Breast Cancer Res, 2011 , 13(2) :R46.
4Lewis Phillips GD, Li G, Dugger DL, et al. Targeting Her2- positive breast cancer with trastuzumab-DMl , an antibodycytotoxic drug conjugate [ J ]. Cancer Res, 2008, 68 (22) :9280 -9290.
5Junutula JR, Flagella KM Graham RA et al. Engineered thio-trastuzumab-DM 1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer[J]. Clin Cancer Res, 2010, 16(19) : 4769 -4778.
6Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 ( Her2 ) - positive breast cancer after prior Her2- directed therapy [ J ] . J Clin Oncol, 2011, 29(4) :398 -405.
7Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DMl , an Her2 antibody-drug conjugate, given every 3 weeks to patients with Her2-positive metastatic breast cancer [J]. J Clin Oncol, 2010, 28(16) :2698 -2704.
8Miller k, Gianni L, Andre F, et al. A phase lb/II trial of trastuzumab-DMl ( T-DM1 ) with pertuzumab (P) for women with Her2-positive, locally advanced or metastatic breast cancer ( BC ) who were previously treated with trastuzumab (T) [ J]. J Clin Oncol, 2010, 28 (suppl;abstr 1012) :l17s.
9Porter JR, Fritz CC, Depew KM. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy [J]. Curr Opin Chem Biol, 2010, 14(3) :412 -420.
10Modi S, Stopeck AT, Linden HM, et al. HSP90 Inhibition is Effective in Breast Cancer: A Phase 2 Trial of Tanespimycin ( 17 AAG) plus Trastuzumab in Patients with Her2- Positive Metastatic Breast Cancer Progressing on Trastuzumab [ J ] . Clin Cancer Res, 2011 , 10:Epub ahead of print.
